How much bacteriostatic water with BPC-157?
Most research-handling protocols reconstitute a 10 mg BPC-157 vial with 2 mL or 3 mL of bacteriostatic water. Two millilitres yields a 5 mg/mL working concentration; three millilitres yields 3.33 mg/mL. The specific volume chosen sets the dose-per-syringe-unit math for the downstream experimental dosing.
What the research literature says
BPC-157 is supplied as a lyophilised white powder in a sealed vial under inert gas (see the lyophilized entry for the physical-chemistry basis of the dry-form supply). Reconstitution converts the dry powder into a working solution that can be drawn into an insulin syringe for measurement.
The choice of reconstitution volume is an experimental-design decision rather than a fixed protocol. Two common reference points appear across the published handling literature and vendor protocols. A 2 mL fill of bacteriostatic water gives a 5 mg/mL concentration on a 10 mg vial; an insulin syringe graduated in 100-unit increments where 100 units equals 1 mL delivers 50 µg per syringe unit at this concentration. A 3 mL fill gives 3.33 mg/mL, where 100 units delivers ~33 µg. Lower volumes (1 mL = 10 mg/mL = 100 µg per unit) are used when the protocol calls for higher per-draw doses; higher volumes are used when finer dose-resolution is required.
Bacteriostatic water is the standard diluent because the 0.9% benzyl alcohol preservative supports multi-dose draw across the multi-week post-reconstitution stability window of the compound. Sterile water for injection (preservative-free, single-use) is the alternative when benzyl-alcohol incompatibility is a concern, but the BPC-157 published literature does not document benzyl-alcohol incompatibility for the peptide. The lyophilisation-stability literature (PMID 10967427, PMID 15032301) consolidates the broader framework for post-reconstitution stability of lyophilised peptide formulations.
Why this matters in research context
The reconstitution-volume decision sets the entire downstream experimental dosing math. Once a volume is chosen and the powder dissolved, the working concentration is fixed for the life of that vial — the only way to change it is to draw the remaining volume into a new container with additional diluent. Most research workflows pick a volume that lets the typical per-experiment dose draw to a round number of insulin-syringe units (e.g., a 250 µg dose at 5 mg/mL = 5 units, vs the same dose at 3.33 mg/mL = 7.5 units), simplifying bench arithmetic and reducing per-draw measurement error. The full reconstitution-math protocol with syringe-IU conversion tables is consolidated in the reconstitution guide.
Related compounds
- BPC-157 10mg — the single-compound vial covered by this answer
- Wolverine Stack (BPC-157 + TB-500 blend) — combined-formulation vial; reconstitution math identical at the per-vial level
- BPC-157 (glossary entry) — chemical identifiers, sequence, mechanism summary
Related research questions
- How do you store lyophilized peptides?
- Can BPC-157 be stacked with TB-500?
- How long does reconstituted semaglutide last?
References
- Wang W. Lyophilization and development of solid protein pharmaceuticals. International Journal of Pharmaceutics 2000;203(1-2):1-60. [PMID 10967427]
- Tang X, Pikal MJ. Design of freeze-drying processes for pharmaceuticals: practical advice. Pharmaceutical Research 2004;21(2):191-200. [PMID 15032301]
- USP <1231> Water for Pharmaceutical Purposes — Bacteriostatic Water for Injection monograph; composition, in-use stability, and preservative-content specifications.
Research-questions pages describe research-context use of peptide-research terminology. They do not constitute medical, veterinary, or clinical advice. BPC-157 is sold strictly as a research-grade reagent for laboratory and bench research applications.